| dc.contributor.author |
Zampelas, A |
en |
| dc.date.accessioned |
2014-06-06T06:50:48Z |
|
| dc.date.available |
2014-06-06T06:50:48Z |
|
| dc.date.issued |
2010 |
en |
| dc.identifier.issn |
00219150 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1016/j.atherosclerosis.2010.06.018 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/5167 |
|
| dc.subject.other |
docosahexaenoic acid |
en |
| dc.subject.other |
fish oil |
en |
| dc.subject.other |
icosapentaenoic acid |
en |
| dc.subject.other |
intercellular adhesion molecule 1 |
en |
| dc.subject.other |
interleukin 6 |
en |
| dc.subject.other |
metalloproteinase |
en |
| dc.subject.other |
oleic acid |
en |
| dc.subject.other |
omega 6 fatty acid |
en |
| dc.subject.other |
phospholipid |
en |
| dc.subject.other |
atherosclerotic plaque |
en |
| dc.subject.other |
cardiovascular disease |
en |
| dc.subject.other |
cardiovascular risk |
en |
| dc.subject.other |
clinical trial |
en |
| dc.subject.other |
diet supplementation |
en |
| dc.subject.other |
dietary intake |
en |
| dc.subject.other |
human |
en |
| dc.subject.other |
inflammation |
en |
| dc.subject.other |
lipid composition |
en |
| dc.subject.other |
morbidity |
en |
| dc.subject.other |
mortality |
en |
| dc.subject.other |
note |
en |
| dc.subject.other |
phospholipid blood level |
en |
| dc.subject.other |
priority journal |
en |
| dc.subject.other |
Administration, Oral |
en |
| dc.subject.other |
Capsules |
en |
| dc.subject.other |
Carotid Artery Diseases |
en |
| dc.subject.other |
Dietary Supplements |
en |
| dc.subject.other |
Docosahexaenoic Acids |
en |
| dc.subject.other |
Drug Combinations |
en |
| dc.subject.other |
Eicosapentaenoic Acid |
en |
| dc.subject.other |
Endarterectomy, Carotid |
en |
| dc.subject.other |
Foam Cells |
en |
| dc.subject.other |
Gene Expression Regulation |
en |
| dc.subject.other |
Humans |
en |
| dc.subject.other |
Inflammation |
en |
| dc.subject.other |
Inflammation Mediators |
en |
| dc.subject.other |
Matrix Metalloproteinases |
en |
| dc.subject.other |
Phospholipids |
en |
| dc.subject.other |
Preoperative Care |
en |
| dc.subject.other |
Rupture, Spontaneous |
en |
| dc.subject.other |
T-Lymphocytes |
en |
| dc.subject.other |
Treatment Outcome |
en |
| dc.title |
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability |
en |
| heal.type |
other |
en |
| heal.identifier.primary |
10.1016/j.atherosclerosis.2010.06.018 |
en |
| heal.publicationDate |
2010 |
en |
| heal.abstract |
[No abstract available] |
en |
| heal.journalName |
Atherosclerosis |
en |
| dc.identifier.issue |
1 |
en |
| dc.identifier.volume |
212 |
en |
| dc.identifier.doi |
10.1016/j.atherosclerosis.2010.06.018 |
en |
| dc.identifier.spage |
34 |
en |
| dc.identifier.epage |
35 |
en |